Clark K R, Taylor R M, Forsythe J L
Department of Transplantation Surgery, Royal Victoria Infirmary, Newcastle upon Tyne, England.
Clin Transpl. 1993:267-74.
Recently, our unit has used a polyclonal antilymphocyte agent frequently to treat steroid-resistant rejection or induce immunosuppression. A system of monitoring has been developed to govern the use of this powerful agent. This technique has allowed reduction in the total dose of ATG with no loss of efficacy but a decrease in the rate of serious viral infection. Powerful polyclonal agents remain an important element of immunosuppression provided that the dose of the agent is tailored to the individual response.
最近,我们单位频繁使用一种多克隆抗淋巴细胞制剂来治疗激素抵抗性排斥反应或诱导免疫抑制。已开发出一套监测系统来管理这种强效制剂的使用。这项技术使得抗胸腺细胞球蛋白(ATG)的总剂量得以减少,而疗效并未降低,但严重病毒感染率有所下降。只要根据个体反应调整制剂剂量,强效多克隆制剂仍是免疫抑制的重要组成部分。